Atlas Trials

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT06295549 · TERMINATED

Trial details

NCT number
NCT06295549
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Start date
2024-04-11
Primary completion
2025-06-11
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.